A Phase 1 interventional study of Topical steroid (Dexamethasone) and Topical antihistamine (Diphenhydramine) in Healthy, sponsored by Otsuka Pharmaceutical Co., Ltd.. Completed at 2 sites in Korea, Republic of. Open to participants aged 20 Years to 45 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2014-04-29.
Sponsored by Otsuka Pharmaceutical Co., Ltd. (part of Otsuka Holdings Co., Ltd.) · Phase 1, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
To investigate the efficacy of symptomatic therapy with topical steroids and antihistamines for application site reaction (ASR) after administration of SPM 962 in healthy subjects
Otsuka Pharmaceutical Co., Ltd. is the lead sponsor of 143 studies on the registry; 11 are open to participants now.
Counted across the registry records on this site, refreshed daily.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.
The study may name a correction formula and a limit in milliseconds, often around 450–480.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
BMI (body mass index)
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ECG (electrocardiogram)
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Postmenopausal
Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
QT and QTc
On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.
The study may name a correction formula and a limit in milliseconds, often around 450–480.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis B tests
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis C tests
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Topical medication of steroid (Dexamethasone) to the application sites after the patch removal
Drug: Topical steroid (Dexamethasone)
Topical medication of antihistamine(Diphenhydramine) to the application sites after the patch removal
Drug: Topical antihistamine (Diphenhydramine)
No treatment to the application sites after the patch removal
for SPM 962: 1 mg/24h patch for 48 hours as Acceleration period, then 2 mg/24h patch to the other site for 24 hours as Dose-escalation period, for steroid: twice daily administration of Dexamethasone (1 mg/g cream) to the application sites after the patch removal
for SPM 962: 1 mg/24h patch for 48 hours as Acceleration period, then 2 mg/24h patch to the other site for 24 hours as Dose-escalation period, for antihistamine: twice daily administration of Diphenhydramine (10 mg/g cream) to the application sites after the patch removal
Skin Irritation Score of the Application Site
Skin irritation score of the application site 24 hours after 2 mg/24 hour patch removal (dose-escalation period) and difference between Steroid or Antihistamine and No-treatment. The scale scoring criteria are 0(-): Negative, 0.5(±): Faint erythema, 1(+): Erythema, 2(++): Erythema + edema, 3(+++): Erythema + edema + papules, serous papule, vesicles, 4(++++): Coalescing vesicles.
Time frame: 24 hours after 2 mg/24 hr patch removal
Itching of Application Site Evaluated by the Visual Analogue Scale (VAS)
Itching of application site evaluated by the visual analogue scale (VAS) 24 hours after 2 mg/24 hour patch removal (dose-escalation period) and difference between Steroid or Antihistamine and No-treatment. The score ranges from 0 (no itching) to 100 (strongest imaginable itching).
Time frame: 24 hours after 2 mg/24 hr patch removal
Skin Irritation Score After Patch Removal
Numbers of subjects with each skin irritation score. The scale scoring criteria are 0(-): Negative, 0.5(±): Faint erythema, 1(+): Erythema, 2(++): Erythema + edema, 3(+++): Erythema + edema + papules, serous papule, vesicles, 4(++++): Coalescing vesicles.
Time frame: Up to 72 hours after patch removal
Itching of Application Site Evaluated by VAS After Patch Removal
Changes of itching of application site evaluated by VAS after patch removal (acceleration and dose-escalation periods). The score ranges from 0 (no itching) to 100 (strongest imaginable itching).
Time frame: Up to 96 hours after patch removal
| Milestone | Topical Steroid | Topical Antihistamine | No-treatment |
|---|---|---|---|
| Started | 38 | 40 | 39 |
| Completed | 38 | 38 | 38 |
| Not completed | 0 | 2 | 1 |
| Withdrew: Withdrawal by subject | 0 | 1 | 1 |
| Withdrew: Physician decision | 0 | 1 | 0 |
Skin irritation score of the application site 24 hours after 2 mg/24 hour patch removal (dose-escalation period) and difference between Steroid or Antihistamine and No-treatment. The scale scoring criteria are 0(-): Negative, 0.5(±): Faint erythema, 1(+): Erythema, 2(++): Erythema + edema, 3(+++): Erythema + edema + papules, serous papule, vesicles, 4(++++): Coalescing vesicles.
| Scores on a scale | Topical Steroid | Topical Antihistamine | No-treatment |
|---|---|---|---|
| Skin Irritation Score of the Application Site | 0.237 (0.084 to 0.390) | 0.289 (0.136 to 0.422) | 0.250 (0.101 to 0.399) |
Itching of application site evaluated by the visual analogue scale (VAS) 24 hours after 2 mg/24 hour patch removal (dose-escalation period) and difference between Steroid or Antihistamine and No-treatment. The score ranges from 0 (no itching) to 100 (strongest imaginable itching).
| Scores on a scale | Topical Steroid | Topical Antihistamine | No-treatment |
|---|---|---|---|
| Itching of Application Site Evaluated by the Visual Analogue Scale (VAS) | 1.6 (0.5 to 2.7) | 0.4 (-0.7 to 1.6) | 0.9 (-0.2 to 2.0) |
Numbers of subjects with each skin irritation score. The scale scoring criteria are 0(-): Negative, 0.5(±): Faint erythema, 1(+): Erythema, 2(++): Erythema + edema, 3(+++): Erythema + edema + papules, serous papule, vesicles, 4(++++): Coalescing vesicles.
| Percentage of participants | Topical Steroid | Topical Antihistamine | No-treatment |
|---|---|---|---|
| - (1 hour after patch removal) | 5.3 | 5.6 | 10.0 |
| ± (1 hour after patch removal) | 63.2 | 55.6 | 45.0 |
| + (1 hour after patch removal) | 31.6 | 38.9 | 45.0 |
| - (24 hours after patch removal) | 57.9 | 52.6 | 60.0 |
| ± (24 hours after patch removal) | 36.8 | 36.8 | 30.0 |
| + (24 hours after patch removal) | 5.3 | 10.5 | 10.0 |
| - (48 hours after patch removal) | 89.5 | 94.7 | 80.0 |
| ± (48 hours after patch removal) | 10.5 | 5.3 | 20.0 |
| - (72 hours after patch removal) | 94.4 | 94.7 | 90.0 |
| ± (72 hours after patch removal) | 5.6 | 5.3 | 10.0 |
Changes of itching of application site evaluated by VAS after patch removal (acceleration and dose-escalation periods). The score ranges from 0 (no itching) to 100 (strongest imaginable itching).
| Scores on a scale | Topical Steroid | Topical Antihistamine | No-treatment |
|---|---|---|---|
| 3 hours after patch removal | -2.8 ± 6.9 | -3.0 ± 9.0 | -2.2 ± 4.6 |
| 6 hours after patch removal | -3.3 ± 7.9 | -3.3 ± 8.6 | -2.3 ± 5.0 |
| 24 hours after patch removal | -3.9 ± 10.0 | -2.6 ± 7.0 | -2.6 ± 4.7 |
| 48 hours after patch removal | -3.9 ± 10.5 | -3.6 ± 9.0 | -2.9 ± 5.1 |
| 72 hours after patch removal | -4.1 ± 10.0 | -3.8 ± 8.9 | -3.0 ± 5.1 |
| 96 hours after patch removal | -4.3 ± 10.1 | -3.8 ± 8.9 | -3.0 ± 5.1 |
Collected over 7 days. Non-serious events are listed at a 2% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Over-all | — | 0/120 (0%) | 41/120 (34.2%) |
| Event | Over-all |
|---|---|
| ErythemaSkin and subcutaneous tissue disorders | 29/120 |
| HeadacheNervous system disorders | 6/120 |
| SomnolencePsychiatric disorders | 6/120 |
| Oropharyngeal PainRespiratory, thoracic and mediastinal disorders | 6/120 |
| RhinorrhoeaRespiratory, thoracic and mediastinal disorders | 4/120 |
| Application Site IrritationGeneral disorders | 3/120 |
| Feeling HotGeneral disorders | 3/120 |
| Age, Continuous(years) | Topical Steroid | Topical Antihistamine | No-treatment | Total |
|---|---|---|---|---|
| Mean | 26.7 ± 4.2 | 26.7 ± 4.8 | 26.1 ± 3.7 | 26.5 ± 4.3 |
| Age, Categorical(Participants) | Topical Steroid | Topical Antihistamine | No-treatment | Total |
|---|---|---|---|---|
| <=18 years | 0 | 0 | 0 | 0 |
| Between 18 and 65 years | 38 | 40 | 39 | 117 |
| >=65 years | 0 | 0 | 0 | 0 |
| Sex: Female, Male(Participants) | Topical Steroid | Topical Antihistamine | No-treatment | Total |
|---|---|---|---|---|
| Female | 0 | 0 | 0 | 0 |
| Male | 38 | 40 | 39 | 117 |
| Region of Enrollment(participants) | Topical Steroid | Topical Antihistamine | No-treatment | Total |
|---|---|---|---|---|
| Korea, Republic of | 38 | 40 | 39 | 117 |
The record gives a start of Aug 2012, a primary completion of Oct 2012 and a completion of Nov 2012. It does not say whether these dates are actual or estimated.
Results were first posted in Apr 2014, 1 year 6 months after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Mar 2014. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drugs tested here: Steroids · Diphenhydramine
Otsuka Pharmaceutical Co., Ltd. →